A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms SERENADE
- Sponsors Actelion Pharmaceuticals
- 14 Aug 2017 Last checked against ClinicalTrials.gov record.
- 10 Aug 2017 Planned End Date changed from 10 Mar 2020 to 14 Mar 2020.
- 10 Aug 2017 Planned primary completion date changed from 10 Mar 2020 to 14 Mar 2020.